Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) dropped 2.9% on Friday. The company traded as low as $1.69 and last traded at $1.69. 159,996 shares changed hands during trading, a decline of 58% from the average daily volume of 383,153 shares. The stock had previously closed at $1.74.
Analyst Ratings Changes
Several equities analysts recently issued reports on HCAT shares. Citigroup cut their price target on shares of Health Catalyst from $2.50 to $2.00 and set a "neutral" rating for the company in a report on Tuesday, August 11th. Canaccord Genuity Group reaffirmed a "hold" rating and set a $1.80 price objective (down from $3.00) on shares of Health Catalyst in a research note on Thursday, August 20th. Weiss Ratings raised shares of Health Catalyst from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, July 28th. Finally, Wells Fargo & Company cut their target price on shares of Health Catalyst from $1.75 to $1.50 and set an "equal weight" rating for the company in a research note on Thursday, August 13th. Two analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Health Catalyst currently has a consensus rating of "Hold" and a consensus price target of $2.15.
Get Our Latest Stock Report on Health Catalyst
Health Catalyst Stock Down 2.9%
The company has a debt-to-equity ratio of 1.51, a quick ratio of 2.70 and a current ratio of 2.70. The firm's 50-day moving average is $1.72 and its two-hundred day moving average is $1.70. The stock has a market cap of $127.19 million, a P/E ratio of -0.46 and a beta of 1.54.
Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.01. The firm had revenue of $70.49 million for the quarter, compared to analyst estimates of $69.09 million. Health Catalyst had a negative return on equity of 1.83% and a negative net margin of 90.61%. On average, equities research analysts anticipate that Health Catalyst, Inc. will post -0.18 earnings per share for the current year.
Insider Transactions at Health Catalyst
In other Health Catalyst news, CEO Simeon Kohl acquired 59,000 shares of Health Catalyst stock in a transaction on Monday, September 14th. The shares were purchased at an average cost of $1.79 per share, with a total value of $105,610.00. Following the completion of the purchase, the chief executive officer owned 2,856,385 shares in the company, valued at $5,112,929.15. The trade was a 2.11% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 19.40% of the company's stock.
Hedge Funds Weigh In On Health Catalyst
Institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in Health Catalyst during the second quarter valued at approximately $3,654,000. Hsbc Holdings PLC lifted its holdings in Health Catalyst by 313.3% during the second quarter. Hsbc Holdings PLC now owns 408,634 shares of the company's stock worth $809,000 after acquiring an additional 309,766 shares in the last quarter. Palogic Value Management L.P. bought a new position in Health Catalyst during the second quarter worth about $9,796,000. Squarepoint Ops LLC lifted its holdings in Health Catalyst by 1,214.8% during the second quarter. Squarepoint Ops LLC now owns 400,210 shares of the company's stock worth $796,000 after acquiring an additional 369,772 shares in the last quarter. Finally, AXQ Capital LP acquired a new position in Health Catalyst in the second quarter valued at about $38,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.
Health Catalyst Company Profile
(
Get Free Report)
Health Catalyst, Inc provides data and analytics technology and services for healthcare organizations. Its solutions are designed to help hospitals, health systems and other providers organize clinical, operational and financial data, identify opportunities for improvement, and support more informed decisions.
The company's offerings include its Health Catalyst Data Operating System, which integrates and manages healthcare data from multiple sources, along with analytics applications, artificial intelligence and machine-learning capabilities, and tools for population health, quality improvement, cost management and operational performance.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Health Catalyst, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list.
While Health Catalyst currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.